<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255722</url>
  </required_header>
  <id_info>
    <org_study_id>ISO-44-012</org_study_id>
    <nct_id>NCT01255722</nct_id>
  </id_info>
  <brief_title>Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography</brief_title>
  <acronym>X-ACT</acronym>
  <official_title>Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (X-ACT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol
      (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide
      (Ultravist® 370) and iomeprol (Iomeron® 400) in terms of coronary CT scan evaluability
      (quality and interpretability of images).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suspected of coronary artery disease were submitted to coronary CT angiography using
      either iobitridol or contrast agents with higher iodine concentrations (iopromide or
      iomeprol). Independent off-site readers evaluated image quality regarding the ability to
      identify coronary artery stenosis (score 0- non evaluable to 4- excellent quality). The study
      was aimed at showing the non-inferiority of iobitridol in its ability to provide evaluable CT
      scans for the identification of coronary stenosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Patients With Evaluable CT Scans i.e. Allowing Identification of Coronary Artery Stenosis According to Off-site Reading Assessment</measure>
    <time_frame>&lt; 24h</time_frame>
    <description>Evaluability was based upon the off-site assessment of 18-coronary segments graded for image quality with a 5-point scale.4= Excellent quality, fully confidence without any doubts concerning the presence/absence of luminal stenosis; 3= Good quality, confidence concerning the presence/absence of luminal stenosis; 2= Moderate quality, relative confidence, with minor doubts concerning the presence/absence of luminal stenosis; 1= Poor quality, some doubts concerning the presence/absence of stenosis; 0= Non diagnostic.
A patient's CT scan was considered as evaluable for identification of coronary artery stenosis if none of the 18 coronary segments had a score of 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Image Quality According to Off-site Reading</measure>
    <time_frame>&lt;24h</time_frame>
    <description>For each patient, all 18 coronary segments were graded for image quality using a 5-point evaluation scale (from 0=non-diagnostic to 4=excellent). The average image quality was evaluated using the off-site readings, by averaging the scores obtained for the 18 segments used to determine the CT evaluability (primary criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary Track Rate</measure>
    <time_frame>&lt;24h</time_frame>
    <description>A post processing software automatically tracked the number of distal segments of the left anterior descending coronary artery, the left circumflex coronary artery and the right coronary artery . The number of segments tracked per patient were assessed by an independent off-site radiologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Signal Attenuation After IV Injection of Contrast</measure>
    <time_frame>&lt;1h</time_frame>
    <description>Attenuation of signal was measured off-site on post-injection images of four coronary segments, in the ascending aorta and in the left ventricle, then it was averaged at the patient level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Signal-to-Noise Ratio (Average SNR)</measure>
    <time_frame>&lt;1h</time_frame>
    <description>Signal attenuation was measured by off-site radiologists in the lumen of 4 coronary segments, in the ascending aorta and in the left ventricle and was expressed in Hounsfield Unit (HU). Measurements were set in post-injection images for the 6 territories.
A measure of noise in CT scans was collected at least in the aorta and if possible in the muscle and/or air.
Signal-to-Noise Ratios (SNR) of post-injection images were derived in all territories from attenuation measurements according to the following formula:
SNR Territory = Post Attenuation / Image Noise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Contrast-to-noise Ratio (Average CNR)</measure>
    <time_frame>&lt;1h</time_frame>
    <description>Signal attenuation was measured by off-site radiologists in the lumen of 4 coronary segments in the ascending aorta and the in left ventricle and expressed in Hounsfield Unit (HU).
A measure of noise in CT scans was collected at least in the aorta and if possible in the muscle and/or air.
In territories where pre and post signal attenuation measures were both available, the contrast-to-noise ratio was computed according to the following formula: CNR = (Post Att - Baseline Att) / Image Noise</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">468</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Iobitridol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iopromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iomeprol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iobitridol</intervention_name>
    <description>single IV injection</description>
    <arm_group_label>Iobitridol</arm_group_label>
    <other_name>Xenetix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iopromide</intervention_name>
    <description>Single IV injection</description>
    <arm_group_label>Iopromide</arm_group_label>
    <other_name>Ultravist®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iomeprol</intervention_name>
    <description>Single IV injection</description>
    <arm_group_label>Iomeprol</arm_group_label>
    <other_name>Iomeron®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adult patient (having reached legal majority age)

          -  Symptomatic patient suspected for coronary artery disease scheduled for a coronary CT
             angiography

        Exclusion Criteria:

          -  Patient with a heart rate &gt; 65 beats per minute (bpm) and contraindication or
             intolerance to b-blocker administration

          -  Patient with arrhythmia or non-sinus rhythm

          -  Patient with decompensated heart failure

          -  Patient with evidence of ongoing or active clinical instability (suspected or known
             acute myocardial infarction, cardiac shock, acute pulmonary oedema)

          -  Patient who has previously undergone coronary artery bypass graft

          -  Patient who has previously undergone percutaneous transluminal coronary stent
             placement

          -  Patient with artificial heart valve

          -  Patient with known moderate to severe aortic stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin HOFFMANN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Lucerne- Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Chirurgical Marie Lannelongue</name>
      <address>
        <city>Le Plessis Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haut-Lévêque / Radiologie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen - Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint Denis</city>
        <zip>93207</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Radiologie Universitätsklinikum Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>191054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Hospital</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>368167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital LMU</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A.Perrino U.O. di radiodiagnostica</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale del Delta</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapienza-universita di Roma</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale civile Maggiore du Verona Borgo</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Radiologie</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <results_first_submitted>August 27, 2015</results_first_submitted>
  <results_first_submitted_qc>November 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2015</results_first_posted>
  <last_update_submitted>November 12, 2015</last_update_submitted>
  <last_update_submitted_qc>November 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iodinated contrast media, coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 468 patients from 5 European countries were enrolled and evaluated between 3 November 2010 and 17 September 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Iobitridol</title>
          <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
        </group>
        <group group_id="P2">
          <title>Iopromide</title>
          <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
        </group>
        <group group_id="P3">
          <title>Iomeprol</title>
          <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="159"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>asymptomatic patient</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>beta-blocker contraindicated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All included patients set: all included patients, even those who have withdrew prior to contrast injection.</population>
      <group_list>
        <group group_id="B1">
          <title>Iobitridol</title>
          <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
        </group>
        <group group_id="B2">
          <title>Iopromide</title>
          <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
        </group>
        <group group_id="B3">
          <title>Iomeprol</title>
          <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="160"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="468"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="12.2"/>
                    <measurement group_id="B2" value="58.7" spread="11.6"/>
                    <measurement group_id="B3" value="56.9" spread="13.4"/>
                    <measurement group_id="B4" value="57.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Patients With Evaluable CT Scans i.e. Allowing Identification of Coronary Artery Stenosis According to Off-site Reading Assessment</title>
        <description>Evaluability was based upon the off-site assessment of 18-coronary segments graded for image quality with a 5-point scale.4= Excellent quality, fully confidence without any doubts concerning the presence/absence of luminal stenosis; 3= Good quality, confidence concerning the presence/absence of luminal stenosis; 2= Moderate quality, relative confidence, with minor doubts concerning the presence/absence of luminal stenosis; 1= Poor quality, some doubts concerning the presence/absence of stenosis; 0= Non diagnostic.
A patient’s CT scan was considered as evaluable for identification of coronary artery stenosis if none of the 18 coronary segments had a score of 0.</description>
        <time_frame>&lt; 24h</time_frame>
        <population>Full Analysis Set: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Iobitridol</title>
            <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
          </group>
          <group group_id="O2">
            <title>Iopromide</title>
            <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
          </group>
          <group group_id="O3">
            <title>Iomeprol</title>
            <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Patients With Evaluable CT Scans i.e. Allowing Identification of Coronary Artery Stenosis According to Off-site Reading Assessment</title>
          <description>Evaluability was based upon the off-site assessment of 18-coronary segments graded for image quality with a 5-point scale.4= Excellent quality, fully confidence without any doubts concerning the presence/absence of luminal stenosis; 3= Good quality, confidence concerning the presence/absence of luminal stenosis; 2= Moderate quality, relative confidence, with minor doubts concerning the presence/absence of luminal stenosis; 1= Poor quality, some doubts concerning the presence/absence of stenosis; 0= Non diagnostic.
A patient’s CT scan was considered as evaluable for identification of coronary artery stenosis if none of the 18 coronary segments had a score of 0.</description>
          <population>Full Analysis Set: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
          <units>Percentage of patients</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" spread="2.2"/>
                    <measurement group_id="O2" value="95.4" spread="1.7"/>
                    <measurement group_id="O3" value="94.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Iobitridol was compared to the best of the two comparators. The two-sided 95% confidence interval (CI) of the difference between both proportions (Iobitridol - Comparator) was computed and the lower limit of the CI compared to the clinical non-inferiority limit in the study. The non-inferiority of iobitridol over the best comparator was established if the lower limit of the two-sided 95% CI was equal to or higher than the clinical non-inferiority limit.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The clinical non-inferiority margin was set to -10% maximum difference with the best comparator (i.e. iopromide).</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.033</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.088</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Image Quality According to Off-site Reading</title>
        <description>For each patient, all 18 coronary segments were graded for image quality using a 5-point evaluation scale (from 0=non-diagnostic to 4=excellent). The average image quality was evaluated using the off-site readings, by averaging the scores obtained for the 18 segments used to determine the CT evaluability (primary criteria).</description>
        <time_frame>&lt;24h</time_frame>
        <population>Full Analysis Set: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Iobitridol</title>
            <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
          </group>
          <group group_id="O2">
            <title>Iopromide</title>
            <description>Patients were IV injected with a single dose of iopromide before coronary CT angiography</description>
          </group>
          <group group_id="O3">
            <title>Iomeprol</title>
            <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Average Image Quality According to Off-site Reading</title>
          <description>For each patient, all 18 coronary segments were graded for image quality using a 5-point evaluation scale (from 0=non-diagnostic to 4=excellent). The average image quality was evaluated using the off-site readings, by averaging the scores obtained for the 18 segments used to determine the CT evaluability (primary criteria).</description>
          <population>Full Analysis Set: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
          <units>Image quality Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="0.9"/>
                    <measurement group_id="O2" value="3.5" spread="0.8"/>
                    <measurement group_id="O3" value="3.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.750</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coronary Track Rate</title>
        <description>A post processing software automatically tracked the number of distal segments of the left anterior descending coronary artery, the left circumflex coronary artery and the right coronary artery . The number of segments tracked per patient were assessed by an independent off-site radiologist.</description>
        <time_frame>&lt;24h</time_frame>
        <population>Full Analysis Set population: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Iobitridol</title>
            <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
          </group>
          <group group_id="O2">
            <title>Iopromide</title>
            <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
          </group>
          <group group_id="O3">
            <title>Iomeprol</title>
            <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Track Rate</title>
          <description>A post processing software automatically tracked the number of distal segments of the left anterior descending coronary artery, the left circumflex coronary artery and the right coronary artery . The number of segments tracked per patient were assessed by an independent off-site radiologist.</description>
          <population>Full Analysis Set population: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
          <units>Number of tracked segments per patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="2.2"/>
                    <measurement group_id="O2" value="10.8" spread="2.4"/>
                    <measurement group_id="O3" value="11.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Signal Attenuation After IV Injection of Contrast</title>
        <description>Attenuation of signal was measured off-site on post-injection images of four coronary segments, in the ascending aorta and in the left ventricle, then it was averaged at the patient level.</description>
        <time_frame>&lt;1h</time_frame>
        <population>Full Analysis Set: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Iobitridol</title>
            <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
          </group>
          <group group_id="O2">
            <title>Iopromide</title>
            <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
          </group>
          <group group_id="O3">
            <title>Iomeprol</title>
            <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Average Signal Attenuation After IV Injection of Contrast</title>
          <description>Attenuation of signal was measured off-site on post-injection images of four coronary segments, in the ascending aorta and in the left ventricle, then it was averaged at the patient level.</description>
          <population>Full Analysis Set: all patients who underwent the coronary CT scan examination and had available assessments of the primary endpoint.</population>
          <units>Hounsfield Units</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426.3" spread="92.9"/>
                    <measurement group_id="O2" value="449.8" spread="88.1"/>
                    <measurement group_id="O3" value="466.4" spread="104.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Signal-to-Noise Ratio (Average SNR)</title>
        <description>Signal attenuation was measured by off-site radiologists in the lumen of 4 coronary segments, in the ascending aorta and in the left ventricle and was expressed in Hounsfield Unit (HU). Measurements were set in post-injection images for the 6 territories.
A measure of noise in CT scans was collected at least in the aorta and if possible in the muscle and/or air.
Signal-to-Noise Ratios (SNR) of post-injection images were derived in all territories from attenuation measurements according to the following formula:
SNR Territory = Post Attenuation / Image Noise</description>
        <time_frame>&lt;1h</time_frame>
        <population>Full Analysis Set: included all patients who underwent the examination and had available assessments of the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Iobitridol</title>
            <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
          </group>
          <group group_id="O2">
            <title>Iopromide</title>
            <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
          </group>
          <group group_id="O3">
            <title>Iomeprol</title>
            <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Average Signal-to-Noise Ratio (Average SNR)</title>
          <description>Signal attenuation was measured by off-site radiologists in the lumen of 4 coronary segments, in the ascending aorta and in the left ventricle and was expressed in Hounsfield Unit (HU). Measurements were set in post-injection images for the 6 territories.
A measure of noise in CT scans was collected at least in the aorta and if possible in the muscle and/or air.
Signal-to-Noise Ratios (SNR) of post-injection images were derived in all territories from attenuation measurements according to the following formula:
SNR Territory = Post Attenuation / Image Noise</description>
          <population>Full Analysis Set: included all patients who underwent the examination and had available assessments of the primary endpoint.</population>
          <units>Hounsfield Units:Hounsfield Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="5.6"/>
                    <measurement group_id="O2" value="17.1" spread="5.0"/>
                    <measurement group_id="O3" value="17.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Contrast-to-noise Ratio (Average CNR)</title>
        <description>Signal attenuation was measured by off-site radiologists in the lumen of 4 coronary segments in the ascending aorta and the in left ventricle and expressed in Hounsfield Unit (HU).
A measure of noise in CT scans was collected at least in the aorta and if possible in the muscle and/or air.
In territories where pre and post signal attenuation measures were both available, the contrast-to-noise ratio was computed according to the following formula: CNR = (Post Att – Baseline Att) / Image Noise</description>
        <time_frame>&lt;1h</time_frame>
        <population>Full Analysis Set: included all patients who underwent the examination and had available assessments of the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Iobitridol</title>
            <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography</description>
          </group>
          <group group_id="O2">
            <title>Iopromide</title>
            <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography</description>
          </group>
          <group group_id="O3">
            <title>Iomeprol</title>
            <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography</description>
          </group>
        </group_list>
        <measure>
          <title>Average Contrast-to-noise Ratio (Average CNR)</title>
          <description>Signal attenuation was measured by off-site radiologists in the lumen of 4 coronary segments in the ascending aorta and the in left ventricle and expressed in Hounsfield Unit (HU).
A measure of noise in CT scans was collected at least in the aorta and if possible in the muscle and/or air.
In territories where pre and post signal attenuation measures were both available, the contrast-to-noise ratio was computed according to the following formula: CNR = (Post Att – Baseline Att) / Image Noise</description>
          <population>Full Analysis Set: included all patients who underwent the examination and had available assessments of the primary endpoint.</population>
          <units>Hounsfield Units:Hounsfield Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="5.4"/>
                    <measurement group_id="O2" value="15.3" spread="4.8"/>
                    <measurement group_id="O3" value="15.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post-injection adverse events (i.e. treatment-emergent adverse events) were reported from the time of injection of the contrast media up to 30 minutes after the end of the CT scan exam.</time_frame>
      <desc>The Official French Method of Causality Assessment was used (Begaud B et al. 'Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France'. Therapy. 1985;40:111-8).</desc>
      <group_list>
        <group group_id="E1">
          <title>Iobitridol</title>
          <description>Patients were IV injected with a single dose of iobitridol before a coronary CT angiography
iobitridol: single IV injection</description>
        </group>
        <group group_id="E2">
          <title>Iopromide</title>
          <description>Patients were IV injected with a single dose of iopromide before a coronary CT angiography
iopromide: Single IV injection</description>
        </group>
        <group group_id="E3">
          <title>Iomeprol</title>
          <description>Patients were IV injected with a single dose of iomeprol before a coronary CT angiography
iomeprol: Single IV injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="159"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No unpublished data given to the investigator may be transmitted to a third party without prior approval of the sponsor in writing. The data are the exclusive property of Guerbet.
The investigator undertakes to submit to Guerbet any draft articles or papers related to this study within 30 days of their submission to the scientific review or the congress scientific committee.
All written or oral papers and publications must have the joint agreement of the investigator and the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The main limitation of the study is the absence of gold standard such as conventional angiography to confirm the readers’ assessments. Diagnostic accuracy could therefore not be compared.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Dr. med. Martin HOFFMANN</name_or_title>
      <organization>Section Head Interventional and Cardiac Radiology - Kantonsspital Lucerne, Spitalstrasse, 6006 Lucerne, Switzerland</organization>
      <phone>+41 41 205 4660</phone>
      <email>martin.hoffmann@luks.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

